High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
Diana Crivellari(Centro di Riferimento Oncologico), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Andrea Veronesi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dagmar Hess(Kantonsspital St. Gallen), Beat Thürlimann(University of St.Gallen), Davide Lombardi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giovanni Martinelli(University of Bologna), Jean Bauer(European Institute of Oncology), Franco Nolè(European Institute of Oncology), Cristiana Sessa(Institute of Oncology Research), Markus Borner(University of Bern), Olivia Pagani(Swiss Group For Clinical Cancer Research), Rossella Graffeo(Ente Ospedaliero Cantonale)
Cited by 151
Related Papers
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k